These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 15154832)

  • 1. Managing the interface with marketing to improve delivery of pharmacovigilance within the pharmaceutical industry.
    Edwards B
    Drug Saf; 2004; 27(8):609-17. PubMed ID: 15154832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
    Tsintis P; La Mache E
    Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ethics of the medical-pharmaceutical relationship.
    Vashi NA; Latkowski JA
    Clin Dermatol; 2012; 30(2):188-91. PubMed ID: 22330662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unhealthy marketing of pharmaceutical products: An international public health concern.
    Mulinari S
    J Public Health Policy; 2016 May; 37(2):149-59. PubMed ID: 26911654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Early achievements of the Danish pharmaceutical industry-7].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2014; (42):31-62. PubMed ID: 25816561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The marketing of pharmaceutical agents: friend or foe?
    Jurd S
    Australas Psychiatry; 2010 Apr; 18(2):97-100. PubMed ID: 20307151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "But doctors do it...": nurses' views of gifts and information from the pharmaceutical industry.
    Jutel A; Menkes DB
    Ann Pharmacother; 2009 Jun; 43(6):1057-63. PubMed ID: 19470854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The art and science of risk management: a US research-based industry perspective.
    Bush JK; Dai WS; Dieck GS; Hostelley LS; Hassall T
    Drug Saf; 2005; 28(1):1-18. PubMed ID: 15649102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective executive management in the pharmaceutical industry.
    Tran H; Kleiner BH
    J Health Care Finance; 2005; 32(1):8-15. PubMed ID: 18972973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Communication and the Pharmaceutical Industry: what is the reality?
    Edwards B; Chakraborty S
    Drug Saf; 2012 Nov; 35(11):1027-40. PubMed ID: 23061779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel therapeutics risk management].
    Hagemann U
    Z Evid Fortbild Qual Gesundhwes; 2009; 103(5):269-72. PubMed ID: 19645340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethical code of the pharmaceutical industry in Slovakia. (Excerpts).
    Med Etika Bioet; 2004; 11(3-4):11-22. PubMed ID: 16294449
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacovigilance strategy: opportunities for cross-national learning.
    Fermont I
    Isr J Health Policy Res; 2019 Jun; 8(1):54. PubMed ID: 31217025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacovigilance: An Overview.
    Beninger P
    Clin Ther; 2018 Dec; 40(12):1991-2004. PubMed ID: 30126707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A risk-based approach to scheduling audits.
    Rönninger S; Holmes M
    PDA J Pharm Sci Technol; 2009; 63(6):575-88. PubMed ID: 20169864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
    Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
    Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease awareness advertising (DAA) in emerging economy: A comparison between views of consumers and pharmaceutical professionals.
    Banerjee S; Dash SK
    Health Mark Q; 2018; 35(2):134-150. PubMed ID: 30321128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.